



ASX Release
2 March 2020

LITTLE GREEN PHARMA LAUNCHES FOURTH MEDICINAL CANNABIS OIL PRODUCT

Highlights:

- Little Green Pharma expands its LGP Classic product range with release of the first Australian made whole plant CBD cannabis oil product for the Australian market, **LGP Classic CBD 50**
- **LGP Classic CBD 50** is a Schedule 4 medicine, and only requires TGA approval, simplifying the prescription pathway for healthcare practitioners
- LGP has listed its three existing **LGP Classic** products for export on the ARTG and is in the process of listing **LGP Classic CBD 50** for export

Little Green Pharma Ltd (ASX: LGP) ("LGP" or the "Company") is pleased to announce the launch of its new medicinal cannabis oil product, **LGP Classic CBD 50**.

LGP Classic CBD 50 is a whole plant extract cannabidiol ("CBD") oil containing 50mg/mL CBD and no tetrahydrocannabinol ("THC") and complements LGP's existing product range, which comprises:

- **LGP Classic 20:5**, a higher THC ratio product;
- **LGP Classic 10:10**, a balanced THC and CBD ratio product; and
- **LGP Classic 1:20**, a higher CBD ratio product.

LGP's existing range of three **LGP Classic** products are already listed on the Australian Register of Therapeutic Goods ("ARTG") for export, and the Company is currently seeking approval for the **LGP Classic CBD 50** product on the ARTG.

Commenting on the launch of **LGP Classic CBD 50**, LGP Managing Director Fleta Solomon said: *"The launch of the LGP Classic CBD 50 product is another major milestone for the Company, and we are excited to add it to our suite of Australian-made GMP manufactured products for supply to healthcare practitioners and their patients globally."*

"LGP is now able to meet healthcare practitioners' needs for a higher CBD ratio product. This is in addition to LGP's 'Classic' product suite of cannabinoid medicines, all of which are locally made and GMP manufactured."

"LGP has been supplying patients with medical grade cannabis oils since the launch of our first medicines in August 2018. We are committed to making the highest quality cannabinoid medicines accessible and available to all patients."

LGP Classic CBD 50 is classified as a Schedule 4 medicine, which simplifies the prescription pathway for healthcare practitioners in Australia, as it does not require State Health approval in addition to TGA approval.



Recent data indicates that approximately 23% of all medicinal cannabis products prescribed in Australia (up to 31 December 2019) were CBD products, with cannabis oil oral solutions the most commonly prescribed medicinal cannabis product.¹

Since launching its first medicinal cannabis product in August 2018, LGP and its exclusive GMP-licensed manufacturing partner have accrued more than one and a half years of experience and expertise in developing, cultivating, manufacturing and selling medicinal cannabis products in Australia, as well as developing relationships with medical practitioners nationally. This experience and GMP capability strongly position LGP to continue developing international pathways for the supply of its medicinal cannabis products into global markets.

ENDS

For interviews, export updates, clinical study protocols and patient case studies please contact:

David Tasker
Chapter One Advisors

E: dtasker@chapteroneadvisors.com.au

M: +61 433 112 936

Celia Young, Marketing Manager
Little Green Pharma

E: celia@lgpharma.com.au

M: +61 421 730 885

For more information about Little Green Pharma go to: www.littlegreenpharma.com

BY ORDER OF THE BOARD

A handwritten signature in black ink, appearing to read "Craig Basson".

Craig Basson
Company Secretary

¹ Submission to the Senate Community Affairs Reference Committee, Senate inquiry into the current barriers to patient access to medicinal cannabis in Australia (p 16 and p17)